NOSOPHARM AND GNA NOW ANNOUNCE POSITIVE RESULTS FOR THE LATE PRECLINICAL DEVELOPMENT OF THE FIRST-IN-CLASS ANTIBIOTIC NOSO-502

An important milestone has been reached for the GNA NOW Consortium, which BIOASTER is proud to be a partner of. A Go-decision has been received for the project’s NOSO-502 program to continue preparations for the first-in-human Phase 1 clinical study! This decision demonstrates the quality and innovativeness of NOSO-502, which has the potential to treat life-threatening multidrug-resistant infections.

Antimicrobials are the backbone of modern medicine, allowing us to treat infections. However, the overuse and misuse of antimicrobials are driving drug-resistant pathogens, leading to an increasingly urgent global health crisis. We are proud to play our part in tackling antimicrobial resistance (#AMR) by partnering with the GNA NOW Consortium. Thank you to our fellow partners and our funders for working with us on this increasingly important topic!

NOSO-502 is being developed by Nosopharm in partnership with GNA NOW, a #publicprivatepartnership funded by the Innovative Medicines Initiative 2 (IMI2), now the Innovative Health Initiative (IHI)